Biotech and Pharmaceuticals
The 11 GRANOLAS shares power Europe to file highs, drawing Magnificent Seven comparisons
The German share selling price index DAX graph is pictured at the inventory trade in Frankfurt, Germany, January 19, 2024. Employees | Reuters Above the last 12 months, just 11 shares manufactured up half of the gains that driven the pan-European Stoxx 600 stock index to a document-large close on Friday. Earlier this month, Goldman […]
Read More
The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs […]
Read More
Novavax to settle dispute over canceled Covid vaccine purchase agreement
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a […]
Read More
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge […]
Read More
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But before we get into the numbers, […]
Read More
AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters AbbVie on Tuesday said longtime executive Robert Michael will become the company’s new CEO, replacing Richard Gonzalez. Michael, who is AbbVie’s president and chief operating officer, will become the company’s second-ever CEO […]
Read More
Elon Musk states initial Neuralink individual can regulate a personal computer mouse by way of thinking
Jonathan Raa | Nurphoto | Getty Illustrations or photos A affected person implanted with Neuralink’s mind technological know-how can now handle a laptop mouse just by considering, the firm’s founder Elon Musk reported. “(The) patient seems to have built a complete recovery with no ill effects that we are mindful of and is equipped to […]
Read More
'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
There’s been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Overall, 12 mental health disorders affect 970 million people around the world — or one in eight people, according to the Institute for Health Metrics and Evaluation’s Global Burden of Disease. That can mean anything from anxiety and depression to […]
Read More
These are the only 2 ETFs that created dollars every single 12 months for the earlier decade
Two funds investing in defensive shares are the only trade-traded funds in the world that had a good return each yr in excess of the earlier 10 years, CNBC Professional research has discovered. The Amundi ETF MSCI Europe Healthcare UCITS ETF , traded on the London Stock Exchange, and the Canadian customer staples iShares S […]
Read More
What Eli Lilly investors can learn from the slow launch of a competitor's drug
Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is off to a slower-than-expected start. In […]
Read More